Introduction: The EGFR plays a central role in regulating cancer cell growth and survival,
representing an attractive therapeutic target in NSCLC. Areas covered: For the purpose of …

Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal
growth factor receptor (EGFR) was defined as a clinically distinct molecular group. These …

Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been
established as the standard therapy for EGFR-sensitizing mutant advanced non-small-cell …

Lung cancer will be diagnosed in 230,000 patients in the US in 2013. Adenocarcinoma will
be the most common histology, and 10% of lung cancers will be diagnosed in never or …

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …

Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …